Author: admin

Eczema Pipeline, FDA Approvals, Clinical Trials Developments and Companies 2023 | LEO Pharma, GlaxoSmithKline, Arjil Pharmaceuticals, SCM Lifescience, AstraZeneca, Kyowa Kirin, and Others

DelveInsight’s, “Eczema Pipeline Insight 2023” report provides comprehensive insights about 100+ companies and 100+ pipeline drugs in Eczema pipeline landscape. It covers the Eczema pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Eczema pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Key Takeaways from the Eczema Pipeline Report

  • DelveInsight’s Eczema pipeline report depicts a robust space with 100+ active players working to develop 100+ pipeline therapies for Eczema treatment.
  • The leading companies working in the Eczema Market include Kymab, BiomX, LEO Pharma, GlaxoSmithKline, Arjil Pharmaceuticals, SCM Lifescience, Sun Pharmaceutical Industries, Brickell Biotech Inc., Dermira, AstraZeneca, Kyowa Kirin, UCB Biopharma, Arcutis Biotherapeutics, and others.
  • Promising Eczema Pipeline Therapies in the various stages of development include alitretinoin, Arctiva, KY1005, Dupilumab, Lebrikizumab, Baricitinib, MEDI9929, Midazolam, Omeprazole, and others.
  • December 2023: LEO Pharma announced a study of Phase 3 clinical trials for Tralokinumab. The purpose of this study is to test if treatment with tralokinumab is safe and effectful to treat moderate-to-severe atopic hand eczema. This will be judged by a range of assessments that rate the severity and extent of atopic hand eczema and its symptoms, as well as general health status and quality of life.
  • November 2023: Regeneron Pharmaceuticals announced a study of Phase 4 clinical trials for Dupilumab. The study is focused on skin of color participants who have moderate-to-severe atopic dermatitis. Atopic dermatitis, also referred to as eczema, is a condition that causes the skin to become itchy, dry, and cracked. From the previous studies on the study drug, it is seen that the study drug has an acceptable safety and effectiveness in participants with atopic dermatitis. The aim of this study is to get additional information on the safety and effectiveness of the study drug, particularly the information on aspects of atopic dermatitis in skin of color participants.

 

Request a sample and discover the recent advances in Eczema Treatment Drugs @ Eczema Pipeline Outlook Report

 

In the Eczema pipeline report, a detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Eczema collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

 

Eczema Overview

Eczema, also known as atopic dermatitis, is the most common form of dermatitis. Genetic as well as environmental factors are thought to play a part in the pathogenesis. Eczema is most commonly seen in children but can be seen in adults. People with the disease tend to have dry, itchy skin that is prone to infection.

 

Find out more about Eczema Treatment Landscape @ Drugs for Eczema Treatment

 

Eczema Emerging Drugs Profile

  • Amlitelimab: Kymab
  • BX 005: BiomX
  • LP 0145: LEO Pharma

 

Eczema Pipeline Therapeutics Assessment

There are approx. 100+ key companies which are developing the therapies for Eczema. The Eczema companies which have their Eczema drug candidates in the most advanced stage, i.e. phase II include, LEO Pharma.

 

DelveInsight’s Eczema Pipeline Report covers around 100+ products under different phases of clinical development like

  • Late stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates

 

Eczema pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Intra-articular
  • Intraocular
  • Intrathecal
  • Intravenous
  • Ophthalmic
  • Oral
  • Parenteral
  • Subcutaneous
  • Topical
  • Transdermal

 

Eczema Products have been categorized under various Molecule types such as

  • Oligonucleotide
  • Peptide
  • Small molecule

 

Learn more about the emerging Eczema Pipeline Therapies @ Eczema Clinical Trials Assessment

 

Scope of the Eczema Pipeline Report

  • Coverage- Global
  • Eczema Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
  • Eczema Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
  • Eczema Companies- Kymab, BiomX, LEO Pharma, GlaxoSmithKline, Arjil Pharmaceuticals, SCM Lifescience, Sun Pharmaceutical Industries, Brickell Biotech Inc., Dermira, AstraZeneca, Kyowa Kirin, UCB Biopharma, Arcutis Biotherapeutics, and others.
  • Eczema Pipeline Therapies- alitretinoin, Arctiva, KY1005, Dupilumab, Lebrikizumab, Baricitinib, MEDI9929, Midazolam, Omeprazole, and others.

 

Dive deep into rich insights for new drugs for Eczema Treatment, Visit @ Eczema Market Drivers and Barriers, and Future Perspective

 

Table of Content

  1. Introduction
  2. Executive Summary
  3. Eczema: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Eczema– DelveInsight’s Analytical Perspective
  7. Late Stage Products (Phase III)
  8. Drug name : Company name
  9. Drug profiles in the detailed report…..
  10. Mid Stage Products (Phase II)
  11. Amlitelimab: Kymab
  12. Drug profiles in the detailed report…..
  13. Early Stage Products (Phase I)
  14. Drug name : Company name
  15. Drug profiles in the detailed report…..
  16. Preclinical and Discovery Stage Products
  17. Drug name : Company name
  18. Drug profiles in the detailed report…..
  19. Inactive Products
  20. Eczema Key Companies
  21. Eczema Key Products
  22. Eczema- Unmet Needs
  23. Eczema- Market Drivers and Barriers
  24. Eczema- Future Perspectives and Conclusion
  25. Eczema Analyst Views
  26. Eczema Key Companies
  27. Appendix

 

For further information on the Eczema Pipeline Therapeutics, reach out @ Eczema Unmet Needs and Analyst Views

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/behcets-disease-market

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Eczema Pipeline, FDA Approvals, Clinical Trials Developments and Companies 2023 | LEO Pharma, GlaxoSmithKline, Arjil Pharmaceuticals, SCM Lifescience, AstraZeneca, Kyowa Kirin, and Others

Colorectal Cancer Pipeline, FDA Approvals, Clinical Trials Development and Companies 2023 | Mirati Therapeutics, Exelixis, Enterome, Arcus Biosciences, AstraZeneca, Novartis Pharmaceuticals and Others

DelveInsight’s, “Colorectal Cancer Pipeline Insight 2023” report provides comprehensive insights about 145+ companies and 150+ pipeline drugs in the Colorectal Cancer pipeline landscape. It covers the Colorectal Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Colorectal Cancer pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Key Takeaways from the Colorectal Cancer Pipeline Report

  • DelveInsight’s Colorectal Cancer pipeline report depicts a robust space with 145+ active players working to develop 150+ pipeline therapies for Colorectal Cancer treatment.
  • The leading companies working in the Colorectal Cancer Market include Mirati Therapeutics, Exelixis, Enterome, Arcus Biosciences, Lyell Immunopharma, AstraZeneca, Novartis Pharmaceuticals, Surgimab, Numab Therapeutics, SOTIO Biotech, Amgen, Sichuan Baili Pharmaceutical, Qilu Pharmaceutical, Bristol-Myers Squibb, NGM Biopharmaceuticals, Takeda, PureTech, Pfizer, Kezar Life Sciences, Salubris Biotherapeutics, and others.
  • Promising Colorectal Cancer Pipeline Therapies in the various stages of development include CPT-11 and TS-1, ZN-c3, Encorafenib, Cetuximab, Bevacizumab, Oxaliplatin, Capecitabine, and others.
  • December 2023: Boehringer Ingelheim announced a study of Phase 1 clinical trials for Ezabenlimab, BI 765063, and Pembrolizumab. This study is open to people with newly diagnosed colorectal cancer. People who are scheduled for surgery can participate. People either get a medicine called BI 765063 combined with ezabenlimab or combined with pembrolizumab in preparation of the upcoming surgery. The tested medicines in this study are antibodies that may help the immune system fight cancer. The purpose of this study is to find out how well people with early colorectal cancer can tolerate treatment with these medicines. The study also looks at whether the tumor changes.
  • October 2023: Arcus Biosciences Inc. announced a study of phase 1 & 2 clinical trials for AB680, Etrumadenant, Zimberelimab, and Bevacizumab. This randomized phase 1b/2 open-label study will evaluate the antitumour activity and safety of etrumadenant (AB928) treatment combinations in participants with metastatic colorectal cancer. This is a multicenter, open-label Phase 1b/2 study in participants with metastatic colorectal cancer that will assess the antitumour activity and safety of etrumadenant.
  • October 2023: Bristol-Myers Squibb announced a study of phase 3 clinical trials for Ipilimumab and Oxaliplatin. The main purpose of this study is to compare the clinical benefit, as measured by Progression-Free Survival (PFS), Objective Response Rate (ORR), and Overall Survival (OS), achieved by nivolumab in combination with ipilimumab or by nivolumab monotherapy in participants with Microsatellite Instability High (MSI-H) or Mismatch Repair Deficient (dMMR) metastatic colorectal cancer (mCRC). This study will also compare nivolumab plus ipilimumab combination vs chemotherapy for treatment of MSI-H/dMMR mCRC participants.

 

Request a sample and discover the recent advances in Colorectal Cancer Treatment Drugs @ Colorectal Cancer Pipeline Outlook Report

 

In the Colorectal Cancer pipeline report, a detailed description of the drug is given which includes the mechanism of action of the drug, Colorectal Cancer clinical trials studies, NDA approvals (if any), and product development activities comprising the technology, Colorectal Cancer collaborations, licensing, mergers and acquisition, funding, designations and other product-related details.

 

Colorectal Cancer Overview

Colorectal cancer (CRC) is a disorder that occurs exclusively in the colon or rectum and is caused by the colon’s aberrant proliferation of glandular epithelial cells. There are three principal types of CRC: sporadic, hereditary, and colitis-associated. The number of CRC cases is increasing globally day by day. Both environmental and genetic factors determine the risk of developing CRC.

 

Find out more about Colorectal Cancer Therapeutics Assessment @ Colorectal Cancer Preclinical and Discovery Stage Products

 

Colorectal Cancer Emerging Drugs Profile

  • Adagrasib: Mirati Therapeutics
  • XL092: Exelixis
  • EO2040: Enterome
  • Etrumadenant: Arcus Biosciences
  • LYL845: Lyell Immunopharma

 

Colorectal Cancer Pipeline Therapeutics Assessment

There are approx. 145+ key companies which are developing the Colorectal Cancer therapies. The Colorectal Cancer companies which have their Colorectal Cancer drug candidates in the most advanced stage, i.e. phase III include, Mirati Therapeutics.

 

DelveInsight’s Colorectal Cancer pipeline report covers around 150+ products under different phases of clinical development like

  • Late stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates

 

Colorectal Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.

  • Oral
  • Intravenous
  • Subcutaneous
  • Parenteral
  • Topical

 

Colorectal Cancer Products have been categorized under various Molecule types such as

  • Recombinant fusion proteins
  • Small molecule
  • Monoclonal antibody
  • Peptide
  • Polymer
  • Gene therapy

 

Learn more about the emerging Colorectal Cancer Pipeline Therapies @ Colorectal Cancer Clinical Trials Assessment

 

Scope of the Colorectal Cancer Pipeline Report

  • Coverage- Global
  • Colorectal Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
  • Colorectal Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
  • Colorectal Cancer Companies- Mirati Therapeutics, Exelixis, Enterome, Arcus Biosciences, Lyell Immunopharma, AstraZeneca, Novartis Pharmaceuticals, Surgimab, Numab Therapeutics, SOTIO Biotech, Amgen, Sichuan Baili Pharmaceutical, Qilu Pharmaceutical, Bristol-Myers Squibb, NGM Biopharmaceuticals, Takeda, PureTech, Pfizer, Kezar Life Sciences, Salubris Biotherapeutics, and others.
  • Colorectal Cancer Pipeline Therapies- CPT-11 and TS-1, ZN-c3, Encorafenib, Cetuximab, Bevacizumab, Oxaliplatin, Capecitabine, and others.

 

Dive deep into rich insights for new drugs for Colorectal Cancer Treatment, Visit @ Colorectal Cancer Market Drivers and Barriers, and Future Perspective

 

Table of Content

  1. Introduction
  2. Executive Summary
  3. Colorectal Cancer: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Colorectal Cancer– DelveInsight’s Analytical Perspective
  7. Late Stage Products (Phase III)
  8. Adagrasib: Mirati Therapeutics
  9. Drug profiles in the detailed report…..
  10. Mid Stage Products (Phase II)
  11. EO2040: Enterome
  12. Drug profiles in the detailed report…..
  13. Early Stage Products (Phase I)
  14. LYL845: Lyell Immunopharma
  15. Drug profiles in the detailed report…..
  16. Preclinical and Discovery Stage Products
  17. Drug name: Company name
  18. Drug profiles in the detailed report…..
  19. Inactive Products
  20. Colorectal Cancer Key Companies
  21. Colorectal Cancer Key Products
  22. Colorectal Cancer- Unmet Needs
  23. Colorectal Cancer- Market Drivers and Barriers
  24. Colorectal Cancer- Future Perspectives and Conclusion
  25. Colorectal Cancer Analyst Views
  26. Colorectal Cancer Key Companies
  27. Appendix

 

For further information on the Colorectal Cancer Pipeline therapeutics, reach out to Colorectal Cancer Unmet Needs and Analyst Views

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/behcets-disease-market

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Colorectal Cancer Pipeline, FDA Approvals, Clinical Trials Development and Companies 2023 | Mirati Therapeutics, Exelixis, Enterome, Arcus Biosciences, AstraZeneca, Novartis Pharmaceuticals and Others

Idiopathic Pulmonary Fibrosis Pipeline, FDA Approvals, Clinical Trials Developments and Companies 2023 | Novartis, CSL Behring, AstraZeneca, Kadmon Pharmaceuticals, Calliditas Therapeutics, and others

DelveInsight’s, “Idiopathic Pulmonary Fibrosis Pipeline Insight 2023” report provides comprehensive insights about 80+ companies and 100+ pipeline drugs in Idiopathic Pulmonary Fibrosis pipeline landscape. It covers the Idiopathic Pulmonary Fibrosis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Idiopathic Pulmonary Fibrosis pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Key Takeaways from the Idiopathic Pulmonary Fibrosis Pipeline Report

  • DelveInsight’s Idiopathic Pulmonary Fibrosis pipeline report depicts a robust space with 80+ active players working to develop 100+ pipeline therapies for Idiopathic Pulmonary Fibrosis treatment.
  • The leading companies working in the Idiopathic Pulmonary Fibrosis Market include FibroGen, United Therapeutics, Bellerophon Therapeutics, MediciNova, Novartis, Endeavor BioMedicines, Pliant Therapeutics, Nitto Denko, Kadmon Pharmaceuticals, Calliditas Therapeutics, Avalyn Pharmaceuticals, PureTech Health, Taiho Pharmaceutical, Bristol-Myers Squibb, Galecto Biotech AB, CSL Behring, Celgene Pharmaceutical, Vicore Pharma, Boehringer Ingelheim, Guangdong Raynovent, Sunshine Lake Pharma co, Suzhou Zelgen Biopharmaceuticals, Algernon Pharmaceuticals, Horizon Therapeutics, Daewoong Pharmaceutical, Metagone Biotech, AstraZeneca, Lung Therapeutics, Bridge Biotherapeutics, Kinarus AG, Insmed, Reviva Pharmaceuticals, Annapurna Bio, Guangdong Hengrui Pharmaceutical Co., Ltd., Ark Biosciences, Ocean Biomedical, and others.
  • Promising Idiopathic Pulmonary Fibrosis Pipeline Therapies in the various stages of development include DUB program: USP30 Inhibitor, LTI-03, TD-1058, PLN-74809, C21, GB0139, Pamrevlumab, PRM-151, KIN001-IPF, Treprostinil palmitil, AP01, BBT-877, and others.
  • December 2023: Bristol-Myers Squibb announced a study of Phase 3 clinical trials for BMS-986278. The purpose of this study is to evaluate the efficacy, safety, and tolerability of BMS-986278 in participants with Idiopathic Pulmonary Fibrosis.
  • December 2023: United Therapeutics announced a study of Phase 3 clinical trials for Inhaled Treprostinil. Study RIN-PF-302 is designed to evaluate the long-term safety and tolerability of inhaled treprostinil in subjects with idiopathic pulmonary fibrosis.
  • November 2023: Modern Biosciences Ltd. announced a study of Phase 2 clinical trials for Leramistat. This will be a Phase 2, double-blind, placebo-controlled, 2-arm, parallel-group, multi-centre study to investigate leramistat treatment of patients aged 40 years or older with IPF.

 

Request a sample and discover the recent advances in Idiopathic Pulmonary Fibrosis Treatment Drugs @ Idiopathic Pulmonary Fibrosis Pipeline Report

 

In the Idiopathic Pulmonary Fibrosis pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Idiopathic Pulmonary Fibrosis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

 

Idiopathic Pulmonary Fibrosis Overview

Idiopathic pulmonary fibrosis (IPF) is a lung disorder where there is scarring of the lungs from an unknown cause. It is usually a progressive disease with a poor long-term prognosis. The classic features of the disorder include progressive dyspnea and a nonproductive cough. Pulmonary function tests usually reveal restrictive impairment and diminished carbon monoxide diffusing capacity.

 

Find out more about Idiopathic Pulmonary Fibrosis Treatment Landscape @ Drugs for Idiopathic Pulmonary Fibrosis Treatment

 

Idiopathic Pulmonary Fibrosis Emerging Drugs Profile

  • Pamrevlumab: FibroGen
  • Tipelukast: MediciNova
  • PLN-74809: Pliant Therapeutics
  • HZN-825: Horizon Pharmaceuticals
  • Brilaroxazine: Reviva Pharmaceuticals

 

Idiopathic Pulmonary Fibrosis Pipeline Therapeutics Assessment

There are approx. 80+ key companies which are developing the therapies for Idiopathic Pulmonary Fibrosis. The Idiopathic Pulmonary Fibrosis companies which have their Idiopathic Pulmonary Fibrosis drug candidates in the most advanced stage, i.e. phase III include, FibroGen.

 

DelveInsight’s Idiopathic Pulmonary Fibrosis Pipeline Report covers around 80+ products under different phases of clinical development like

  • Late stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates

 

Idiopathic Pulmonary Fibrosis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Oral
  • Parenteral
  • Intravitreal
  • Subretinal
  • Topical

 

Idiopathic Pulmonary Fibrosis Products have been categorized under various Molecule types such as

  • Monoclonal Antibody
  • Peptides
  • Polymer
  • Small molecule
  • Gene therapy

 

Learn more about the emerging Idiopathic Pulmonary Fibrosis Pipeline Therapies @ Idiopathic Pulmonary Fibrosis Clinical Trials Assessment

 

Scope of the Idiopathic Pulmonary Fibrosis Pipeline Report

  • Coverage- Global
  • Idiopathic Pulmonary Fibrosis Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
  • Idiopathic Pulmonary Fibrosis Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
  • Idiopathic Pulmonary Fibrosis Companies- FibroGen, United Therapeutics, Bellerophon Therapeutics, MediciNova, Novartis, Endeavor BioMedicines, Pliant Therapeutics, Nitto Denko, Kadmon Pharmaceuticals, Calliditas Therapeutics, Avalyn Pharmaceuticals, PureTech Health, Taiho Pharmaceutical, Bristol-Myers Squibb, Galecto Biotech AB, CSL Behring, Celgene Pharmaceutical, Vicore Pharma, Boehringer Ingelheim, Guangdong Raynovent, Sunshine Lake Pharma co, Suzhou Zelgen Biopharmaceuticals, Algernon Pharmaceuticals, Horizon Therapeutics, Daewoong Pharmaceutical, Metagone Biotech, AstraZeneca, Lung Therapeutics, Bridge Biotherapeutics, Kinarus AG, Insmed, Reviva Pharmaceuticals, Annapurna Bio, Guangdong Hengrui Pharmaceutical Co., Ltd., Ark Biosciences, Ocean Biomedical, and others.
  • Idiopathic Pulmonary Fibrosis Pipeline Therapies- DUB program: USP30 Inhibitor, LTI-03, TD-1058, PLN-74809, C21, GB0139, Pamrevlumab, PRM-151, KIN001-IPF, Treprostinil palmitil, AP01, BBT-877, and others.

 

Dive deep into rich insights for new drugs for Idiopathic Pulmonary Fibrosis Treatment, Visit @ Idiopathic Pulmonary Fibrosis Market Drivers and Barriers, and Future Perspective

 

Table of Content

  1. Introduction
  2. Executive Summary
  3. Idiopathic Pulmonary Fibrosis: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Idiopathic Pulmonary Fibrosis – DelveInsight’s Analytical Perspective
  7. Late Stage Products (Phase III)
  8. PRM-151: Hoffmann-La Roche
  9. Mid Stage Products (Phase II)
  10. Tipelukast: MediciNova
  11. Early Stage Products (Phase I/II)
  12. Lung stem cells: Regend Therapeutics
  13. Early Stage Products (Phase I)
  14. LTI-03: Lung Therapeutics
  15. Preclinical and Discovery Stage Products
  16. AD-214: Adalta
  17. Inactive Products
  18. Idiopathic Pulmonary Fibrosis Key Companies
  19. Idiopathic Pulmonary Fibrosis Key Products
  20. Idiopathic Pulmonary Fibrosis- Unmet Needs
  21. Idiopathic Pulmonary Fibrosis- Market Drivers and Barriers
  22. Idiopathic Pulmonary Fibrosis- Future Perspectives and Conclusion
  23. Idiopathic Pulmonary Fibrosis Analyst Views
  24. Idiopathic Pulmonary Fibrosis Key Companies
  25. Appendix

 

For further information on the Idiopathic Pulmonary Fibrosis Pipeline Therapeutics, reach out @ Idiopathic Pulmonary Fibrosis Unmet Needs and Analyst Views

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/behcets-disease-market

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Idiopathic Pulmonary Fibrosis Pipeline, FDA Approvals, Clinical Trials Developments and Companies 2023 | Novartis, CSL Behring, AstraZeneca, Kadmon Pharmaceuticals, Calliditas Therapeutics, and others

Major Depressive Disorder Pipeline, FDA Approvals, Clinical Trials Developments and Companies 2023 | GH Research, Praxis Precision Medicines, AbbVie, Gedeon Richter, Bristol-Myers Squibb, and others.

DelveInsight’s, “Major Depressive Disorder Pipeline Insight 2023” report provides comprehensive insights about 75+ companies and 75+ pipeline drugs in the Major Depressive Disorder pipeline landscape. It covers the Major Depressive Disorder pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Major Depressive Disorder pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Key Takeaways from the Major Depressive Disorder Pipeline Report

  • DelveInsight’s Major Depressive Disorder pipeline report depicts a robust space with 75+ active players working to develop 75+ pipeline therapies for Major Depressive Disorder treatment.
  • The leading companies working in the Major Depressive Disorder Market include GH Research, Praxis Precision Medicines, AbbVie, Gedeon Richter, Intra-Cellular Therapies, Bristol-Myers Squibb, Relmada Therapeutics, SAGE Therapeutics, Janssen Research & Development, Minerva Neurosciences, Takeda, Neurocrine Biosciences, Pherin Pharmaceuticals, and others.
  • Promising Major Depressive Disorder Pipeline Therapies in the various stages of development include Brexpiprazole, Desvenlafaxine Succinate Sustained-Release 10mg, Cariprazine, Antidepressant Therapy (ADT), and others.
  • December 2023: Cybin IRL Limited announced a study of Phase 1 & 2 clinical trials for CYB003. The purpose of this study is to determine the safety and tolerability of ascending oral doses of CYB003 in healthy participants with and without major depressive disorder (MDD).
  • November 2023: Neumora Therapeutics Inc. announced a study of Phase 3 clinical trials for NMRA 335140. This is a randomized, double blind, placebo controlled, multicenter study to evaluate the effects of NMRA 335140 (formerly BTRX 335140) on symptoms of depression in participants with Major Depressive Disorder (MDD). The study design consists of a Screening Period (up to 28 days), and a 6-week Treatment Period (during which participants will receive either NMRA 335140 or placebo). At the completion of the 6-week Treatment Period, participants who complete the study, provide informed consent, and meet the eligibility criteria may enter an extension study (NMRA 335140 501).
  • October 2023: Neumora Therapeutics Inc. announced a study of phase 3 clinical trials for NMRA 335140. This is a randomized, double blind, placebo controlled, multicenter study to evaluate the effects of NMRA 335140 (formerly BTRX 335140) on symptoms of depression in participants with Major Depressive Disorder (MDD). The study design consists of a Screening Period (up to 28 days), and a 6-week Treatment Period (during which participants will receive either NMRA 335140 or placebo). At the completion of the 6-week Treatment Period, participants who complete the study, provide informed consent, and meet the eligibility criteria may enter an extension study (NMRA 335140 501).
  • October 2023: Intra-Cellular Therapies Inc. announced a study of Phase 3 clinical trials of Lumateperone. This is a multicenter, randomized, double-blind, placebo-controlled, parallel-group, fixed-dose study in patients with a primary diagnosis of MDD according to criteria of the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) who have an inadequate response to ongoing ADT.

 

Request a sample and discover the recent advances in Major Depressive Disorder Treatment Drugs @ Major Depressive Disorder Pipeline Report

 

In the Major Depressive Disorder pipeline report, a detailed description of the drug is given which includes the mechanism of action of the drug, Major Depressive Disorder clinical trials studies, NDA approvals (if any), and product development activities comprising the technology, Major Depressive Disorder collaborations, licensing, mergers and acquisition, funding, designations and other product-related details.

 

Major Depressive Disorder Overview

Major Depressive Disorder (MDD), also referred to as clinical depression, is a significant medical condition that can affect many areas of your life. It impacts mood and behavior as well as various physical functions, such as appetite and sleep. The exact cause of Major Depressive Disorder isn’t known. However, there are several factors that can increase the risk of developing the condition.

 

Find out more about Major Depressive Disorder Therapeutics Assessment @ Major Depressive Disorder Preclinical and Discovery Stage Products

 

Major Depressive Disorder Emerging Drugs Profile

  • SAGE-217: Sage Therapeutics
  • REL-1017: Relmada Therapeutics, Inc
  • Seltorexant: Minerva Sciences
  • SP-624: Sirtsei Pharmaceuticals, Inc.
  • SPL026: Small Pharma
  • PDC-1421: BioLite Inc

 

Major Depressive Disorder Pipeline Therapeutics Assessment

There are approx. 75+ key companies which are developing the Major Depressive Disorder therapies. The Major Depressive Disorder companies which have their Major Depressive Disorder drug candidates in the most advanced stage, i.e. Preregistration include SAGE Therapeutics.

 

DelveInsight’s Major Depressive Disorder pipeline report covers around 75+ products under different phases of clinical development like

  • Late stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates

 

Major Depressive Disorder pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Oral
  • Subcutaneous
  • Intravenous
  • Intramuscular

 

Major Depressive Disorder Products have been categorized under various Molecule types such as

  • Specific Antibody
  • Peptides
  • Small molecule
  • Gene therapy

 

Learn more about the emerging Major Depressive Disorder Pipeline Therapies @ Major Depressive Disorder Clinical Trials Assessment

 

Scope of the Major Depressive Disorder Pipeline Report

  • Coverage- Global
  • Major Depressive Disorder Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
  • Major Depressive Disorder Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
  • Major Depressive Disorder Companies- GH Research, Praxis Precision Medicines, AbbVie, Gedeon Richter, Intra-Cellular Therapies, Bristol-Myers Squibb, Relmada Therapeutics, SAGE Therapeutics, Janssen Research & Development, Minerva Neurosciences, Takeda, Neurocrine Biosciences, Pherin Pharmaceuticals, and others.
  • Major Depressive Disorder Pipeline Therapies- Brexpiprazole, Desvenlafaxine Succinate Sustained-Release 10mg, Cariprazine, Antidepressant Therapy (ADT), and others.

 

Dive deep into rich insights for new drugs for Major Depressive Disorder Treatment, Visit @ Major Depressive Disorder Market Drivers and Barriers, and Future Perspective

 

Table of Content

  1. Introduction
  2. Executive Summary
  3. Major Depressive Disorder: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Major Depressive Disorder – DelveInsight’s Analytical Perspective
  7. Late Stage Products (Preregistration)
  8. SAGE-217: Sage Therapeutics
  9. Drug profiles in the detailed report…..
  10. Mid Stage Products (Phase II)
  11. SP-624: Sirtsei Pharmaceuticals, Inc.
  12. Drug profiles in the detailed report…..
  13. Early Stage Products (Phase I/II)
  14. SPL026: Small Pharma
  15. Drug profiles in the detailed report…..
  16. Preclinical Stage Products
  17. Drug Name: Company name
  18. Drug profiles in the detailed report…..
  19. Inactive Products
  20. Major Depressive Disorder Key Companies
  21. Major Depressive Disorder Key Products
  22. Major Depressive Disorder- Unmet Needs
  23. Major Depressive Disorder- Market Drivers and Barriers
  24. Major Depressive Disorder- Future Perspectives and Conclusion
  25. Major Depressive Disorder Analyst Views
  26. Major Depressive Disorder Key Companies
  27. Appendix

 

For further information on the Major Depressive Disorder Pipeline therapeutics, reach out to Major Depressive Disorder Unmet Needs and Analyst Views

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/behcets-disease-market

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Major Depressive Disorder Pipeline, FDA Approvals, Clinical Trials Developments and Companies 2023 | GH Research, Praxis Precision Medicines, AbbVie, Gedeon Richter, Bristol-Myers Squibb, and others.

Multiple Sclerosis Pipeline, FDA Approvals, Clinical Trials Development and Companies 2023 | Merck Serono, Bristol- Myers Squibb, Sanofi, Genentech, Novartis Pharmaceuticals, AstraZeneca, and others.

DelveInsight’s, “Multiple Sclerosis Pipeline Insight 2023” report provides comprehensive insights about 100+ companies and 100+ pipeline drugs in the Multiple sclerosis pipeline landscape. It covers the Multiple Sclerosis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Multiple Sclerosis pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Key Takeaways from the Multiple Sclerosis Pipeline Report

  • DelveInsight’s Multiple Sclerosis pipeline report depicts a robust space with 100+ active players working to develop 100+ pipeline therapies for Multiple Sclerosis treatment.
  • The leading companies working in the Multiple Sclerosis Market include TG Therapeutics, Immunic, Atara Biotherapeutics, ANOKION, ImStem Biotechnology, Merck Serono, CinnaGen, Immune Response BioPharma, Inc., Clene Nanomedicine, GeNeuro SA, Sanofi, Bristol-Myers Squibb, HuniLife Biotechnology, Inc., Emerald Health Pharmaceuticals, Biogen, RemeGen Co., Ltd., Antisense Therapeutics, Immune Response BioPharma, Biocad, AB Science, Genentech, Novartis, Pipeline Therapeutics, ASLAN Pharmaceuticals, GlaxoSmithKline, Lucid Psycheceuticals, Voronoi, Hanmi Pharmaceutical, Mapi Pharma, f5 Therapeutics, Autobahn Therapeutics, AstraZeneca, ZyVersa Therapeutics, RedHill Biopharma, Gossamer Bio, Sarepta Therapeutics, BrainStorm Cell Limited, CytoDyn, Pear Therapeutics, ABION, and others.
  • Promising Multiple Sclerosis Pipeline Therapies in the various stages of development rHIgM22, CNTO 1275, Interferon beta-1a (Rebif), alemtuzumab, IMS001, and others.
  • November 2023: Hoffmann-La Roche announced a study of Phase 3 clinical trials for Ocrelizumab and Fingolimod. This double-blind, double-dummy study will evaluate the safety and efficacy of ocrelizumab compared with fingolimod in children and adolescents with relapsing-remitting multiple sclerosis aged between 10 and < 18 years over a duration of at least 96 weeks.
  • October 2023: Hoffmann-La Roche announced a study of phase 3 clinical trials for Ocrelizumab. This double-blind, double-dummy study will evaluate the safety and efficacy of ocrelizumab compared with fingolimod in children and adolescents with relapsing-remitting multiple sclerosis aged between 10 and < 18 years over a duration of at least 96 weeks.
  • September 2023: ImStem Biotechnology announced a study of phase 1 clinical trials for IMS001. This is a Phase 1 study of IMS001, given as a single dose to subjects with Multiple Sclerosis who experience inadequate response and/or intolerability to disease modifying treatments. IMS001 is a human embryonic cell derived (hESC) mesenchymal stem cell (MSC). MSCs have the potential to modulate disease course.

 

Request a sample and discover the recent advances in Multiple Sclerosis Treatment Drugs @ Multiple Sclerosis Pipeline Outlook Report

 

In the Multiple Sclerosis pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Multiple sclerosis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

 

Multiple Sclerosis Overview

Multiple sclerosis (MS) is a chronic disease affecting the central nervous system (the brain and spinal cord).MS occurs when the immune system attacks nerve fibers and myelin sheathing (a fatty substance which surrounds/insulates healthy nerve fibers) in the brain and spinal cord. This attack causes inflammation, which destroys nerve cell processes and myelin – altering electrical messages in the brain. MS is unpredictable and affects each patient differently – some individuals may be mildly affected, while others may lose their ability to write, speak or walk.

 

Find out more about Multiple Sclerosis Therapeutics Assessment @ Multiple Sclerosis Preclinical and Discovery Stage Products

 

Multiple Sclerosis Emerging Drugs Profile

  • Ublituximab: TG Therapeutics
  • IMU-838: Immunic
  • ATA188: Atara Biotherapeutics
  • ANK-700: ANOKION

 

Multiple Sclerosis Pipeline Therapeutics Assessment

There are approx. 100+ key companies which are developing the Multiple sclerosis therapies. The Multiple sclerosis companies which have their Multiple sclerosis drug candidates in the most advanced stage, i.e. preregistration include, TG Therapeutics.

 

DelveInsight’s Multiple Sclerosis Pipeline Report covers around 100+ products under different phases of clinical development like

  • Late stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration

 

Multiple sclerosis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Oral
  • Parenteral
  • Intravenous
  • Subcutaneous
  • Topical.
  • Molecule Type

 

Multiple Sclerosis Products have been categorized under various Molecule types such as

  • Monoclonal Antibody
  • Peptides
  • Polymer
  • Small molecule
  • Gene therapy
  • Product Type

 

Learn more about the emerging Multiple Sclerosis Pipeline Therapies @ Multiple Sclerosis Clinical Trials Assessment

 

Scope of the Multiple Sclerosis Pipeline Report

  • Coverage- Global
  • Multiple Sclerosis Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
  • Multiple Sclerosis Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
  • Multiple Sclerosis Companies- TG Therapeutics, Immunic, Atara Biotherapeutics, ANOKION, ImStem Biotechnology, Merck Serono, CinnaGen, Immune Response BioPharma, Inc., Clene Nanomedicine, GeNeuro SA, Sanofi, Bristol-Myers Squibb, HuniLife Biotechnology, Inc., Emerald Health Pharmaceuticals, Biogen, RemeGen Co., Ltd., Antisense Therapeutics, Immune Response BioPharma, Biocad, AB Science, Genentech, Novartis, Pipeline Therapeutics, ASLAN Pharmaceuticals, GlaxoSmithKline, Lucid Psycheceuticals, Voronoi, Hanmi Pharmaceutical, Mapi Pharma, f5 Therapeutics, Autobahn Therapeutics, AstraZeneca, ZyVersa Therapeutics, RedHill Biopharma, Gossamer Bio, Sarepta Therapeutics, BrainStorm Cell Limited, CytoDyn, Pear Therapeutics, ABION, and others.
  • Multiple Sclerosis Pipeline Therapies- HIgM22, CNTO 1275, Interferon beta-1a (Rebif), alemtuzumab, IMS001, and others

 

Dive deep into rich insights for new drugs for Multiple Sclerosis Treatment, Visit @ Multiple Sclerosis Market Drivers and Barriers, and Future Perspective

 

Table of Content

  1. Introduction
  2. Executive Summary
  3. Multiple sclerosis: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Multiple sclerosis – DelveInsight’s Analytical Perspective
  7. Late Stage Products (Preregistration)
  8. Ublituximab: TG Therapeutics
  9. Drug profiles in the detailed report…..
  10. Mid Stage Products (Phase II)
  11. EHP 101: Emerald Health Pharmaceuticals
  12. Drug profiles in the detailed report…..
  13. Early Stage Products (Phase I)
  14. ASLAN 003: ASLAN Pharmaceuticals
  15. Drug profiles in the detailed report…..
  16. Preclinical and Discovery Stage Products
  17. Lucid MS: FSD Pharma
  18. Drug profiles in the detailed report…..
  19. Inactive Products
  20. Multiple sclerosis Key Companies
  21. Multiple sclerosis Key Products
  22. Multiple sclerosis- Unmet Needs
  23. Multiple sclerosis- Market Drivers and Barriers
  24. Multiple sclerosis- Future Perspectives and Conclusion
  25. Multiple sclerosis Analyst Views
  26. Multiple sclerosis Key Companies
  27. Appendix

 

For further information on the Multiple Sclerosis Pipeline therapeutics, reach out to Multiple Sclerosis Unmet Needs and Analyst Views

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/behcets-disease-market

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Multiple Sclerosis Pipeline, FDA Approvals, Clinical Trials Development and Companies 2023 | Merck Serono, Bristol- Myers Squibb, Sanofi, Genentech, Novartis Pharmaceuticals, AstraZeneca, and others.

Sunny Builders Group Offers Superior Turf Installation Across San Diego

“Sunny Builders Group San Diego”
Sunny Builders Group, a family-owned artificial grass installation company in San Diego County led by CEO Nadav Biderman and manager Sun Barak, now offers superior quality synthetic turf design and build services for residential and commercial backyards, patios, decks, and other outdoor spaces across the region.

San Diego, CA – December 6, 2023 – Sunny Builders Group, led by CEO Nadav Biderman, now provides premium turf installation services for backyards and outdoor spaces across San Diego County. With synthetic grass that looks and feels incredibly realistic, clients can now partner with Sunny Builders to outfit their patio, deck, or entertainment area with lush, ultra-durable turf.

“We leverage the most advanced artificial grass technologies to design and install synthetic lawns perfect for the San Diego climate,” said Biderman. All projects use environmentally friendly, recyclable turf materials that offer a flawless shade match and enjoyment for years.

In addition, Sunny Builders Group offers:

  • Outdoor Kitchens
  • Paver Installation
  • Fire Features
  • Cabanas and Shade Structures
  • Landscaping Services

Serving Carlsbad, Encinitas, Solana Beach, Del Mar, and across greater San Diego, the company provides a tailored approach starting with an in-depth consultation to meet client needs.

Contact manager Sun Barak at (858) 888-1725 or online to schedule a design consultation for your San Diego backyard turf oasis.

About Sunny Builders Group:

Led by CEO Nadav Biderman, Sunny Builders Group is a family-owned business with over 15 years experience constructing patios and technically advanced turf installations across Southern California backyards.

Media Contact
Company Name: Sunny Builders Backyard Design&Remodel
Contact Person: Nadav Biderman
Email: Send Email
Phone: 858 888 1725
Address:6425 Reflection Dr
City: San Diego
State: CA
Country: United States
Website: https://sunnybuildersgroupsd.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Sunny Builders Group Offers Superior Turf Installation Across San Diego

New memoir “Improbable Possibilities” by Linda Rawlings is released, a powerful book for creatives and entrepreneurs that inspires tenacity, exploration, and fearlessness

Observe possibilities.
Entangle possibilities.
Create possibilities.
Throw spaghetti against the wall of life and see what sticks.

“Improbable Possibilities: An Entrepreneur’s Quest” by Linda Rawlings has been released worldwide with paperback, hardcover, and eBook versions available. This 324-page memoir is an incredible story of professional and personal entrepreneurship, following author Linda Rawlings through high and low tech industries, life-affirming adventures, relationships, and creative pursuits, all derived from Linda’s mantra regarding risk:  observe, entangle, create possibilities, and then throw spaghetti–against the walls of your life–to see what sticks.

With a fire for life and a passion for igniting it in others, Rawlings delivers her stories with language that excites readers and inspires them to reach goals. Linda’s journey reveals the creation of an investment and dance career:  the Otis Spunkmeyer, Inc. cookie company and its Triple 888 Manufacturing sheet metal company and DC3 airline Sentimental Journeys; the New Shoes, Old Souls Dance Company; three marriages, two daughters, and so much more. These seemingly disconnected ventures are linked by Linda’s willingness to observe and entangle possibilities, no matter how improbable they might be, and to pitch ideas toward success. This “spaghetti throwing” is a consistent, hopeful message throughout the book. 

Linda’s self-described “personal bias for action” and willingness to take on new challenges have led her down paths of transforming the improbable into the possible. Her true stories provide successful examples of observing unseen opportunities in life, entangling and creating their possibilities, and making success stick.  She inspires readers to embrace chances, navigate setbacks, push beyond potential, harness joy, and live with purpose – all while maintaining a carefree and contagious curiosity. 

The philosophy of “Improbable Possibilities” applies to entrepreneurs, creatives, artists, and anyone looking to expand the possibilities of their lives, even those that seem improbable. Part entertaining memoir and part guidebook for fearless personal growth, Linda’s writing shows how her determination and commitment to exploration have created an uncommon, fulfilling life – and inspires readers to do the same. 

Improbable Possibilities (ISBN: 9781960142177) can be purchased through retailers worldwide, including Barnes & Noble and Amazon. The hardcover retail price is $26.99, the paperback retails for $18.99 and the eBook is available for $2.99. Review copies and interviews are available upon request. 

Learn more at https://lindarawlings.com/

Media Contact
Company Name: MindStir Media LLC
Contact Person: Jen McNabney
Email: Send Email
Phone: 800-767-0531
Address:1 New Hampshire Ave Suite 125
City: Portsmouth
State: NH
Country: United States
Website: https://mindstirmedia.com/

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: New memoir \”Improbable Possibilities\” by Linda Rawlings is released, a powerful book for creatives and entrepreneurs that inspires tenacity, exploration, and fearlessness

Non-Alcoholic Steatohepatitis Pipeline, FDA Approvals, Clinical Trials Developments and Companies 2023 | AstraZeneca, Ionis Pharmaceuticals, NorthSea Therapeutics, Merck, GlaxoSmithKline and Others

DelveInsight’s, “Nonalcoholic Steatohepatitis Pipeline Insight, 2023” report provides comprehensive insights about 100+ companies and 150+ pipeline drugs in Nonalcoholic Steatohepatitis pipeline landscape. It covers the Non-Alcoholic Steatohepatitis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Non-Alcoholic Steatohepatitis pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Key Takeaways from the Non-Alcoholic Steatohepatitis Pipeline Report

  • DelveInsight’s Non-Alcoholic Steatohepatitis pipeline report depicts a robust space with 100+ active players working to develop 150+ pipeline therapies for Non-Alcoholic Steatohepatitis treatment.
  • The leading companies working in the Non-Alcoholic Steatohepatitis Market include Madrigal Pharma, Cirius Therapeutics, AstraZeneca, Ionis Pharmaceuticals, NorthSea Therapeutics, Rivus Pharma, Akero Therapeutics, Merck Sharp & Dohme LLC, Enanta Pharmaceuticals, TaiwanJ Pharmaceuticals, Cascade Pharmaceuticals, Hepion Pharmaceuticals, Chipscreen Biosciences, Boston Pharmaceuticals, Bristol-Myers Squibb, GSK plc., Amgen, Altimmune, Inc., Sciwind Biosciences, SCOHIA PHARMA, Galecto Biotech, J2H Biotech, Tiziana Life Sciences, Palobiofarma, Bird Rock Bio, Ascletis, Liminal BioSciences, ARTham Therapeutics, Pliant Therapeutics, Guangdong Zhongsheng Pharmaceutical, Pharmaxis, Melior Pharmaceuticals, TransThera Biosciences, Cerenis Therapeutics, DURECT Corporation, Enzychem Lifesciences, Ildong Pharmaceutical, LG Chem Life sciences, Gmax Biopharm, Albireo Pharma, InorbitTX, Viking Therapeutics, Ildong Pharmaceutical, Thoth Science, and others
  • Emerging Non-Alcoholic Steatohepatitis Pipeline Therapies in the various stages of development include hydroxychloroquine, Berberine, Digoxin tablet, MK-3655, EDP-305 Dose 2, Atorvastatin, L-Carnitine, Ursodeoxycholic Acid, MRI-PDFF, and others.
  • December 2023: Novo Nordisk A/S announced a study of Phase 3 clinical trials for Semaglutide. The study will last for about 5 years. Participants will have up to 21 clinic visits and 9 phone calls with the clinical staff during the study. Some of the clinic visits may be spread over more than one day. Participants with other chronic liver diseases cannot take part in this study. Women cannot take part in the study if they are pregnant, breast-feeding or plan to become pregnant during the study period.
  • December 2023: Boehringer Ingelheim announced a study of Phase 2 clinical trials for BI 456906.This study is open for men and women with a liver disease called nonalcoholic steatohepatitis (NASH) and liver fibrosis. The purpose of the study is to find out whether a medicine called BI 456906 helps patients with NASH and liver fibrosis. The study tests 3 different doses of BI 456906 to find the dose that helps best. Participants are put into 4 groups randomly, which means by chance. There are 3 groups that each receive a different dose of BI 456906 and there is 1 group that receives placebo. BI 456906 and placebo are given as an injection under the skin once per week. The placebo injection looks like the BI 456906 injection but does not contain any medicine.
  • November 2023: Gilead Sciences announced a study of Phase 2 clinical trials for Semaglutide (SEMA) and Cilofexor (CILO)/Firsocostat (FIR). The goals of this clinical study are to learn more about the study drugs, semaglutide (SEMA) with the fixed-dose combination (FDC) of cilofexor/firsocostat (CILO/FIR), and understand whether they cause fibrosis improvement and Nonalcoholic Steatohepatitis (NASH) resolution in participants with cirrhosis due to NASH.

 

Request a sample and discover the recent advances in Non-Alcoholic Steatohepatitis Treatment Drugs @ Non-Alcoholic Steatohepatitis Pipeline Outlook Report

 

In the Non-Alcoholic Steatohepatitis pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Nonalcoholic Steatohepatitis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

 

Non-Alcoholic Steatohepatitis Overview

Nonalcoholic steatohepatitis (NASH) is liver inflammation and damage caused by a fat buildup in the liver. It is part of a group of conditions called nonalcoholic fatty liver disease. Nonalcoholic fatty liver disease can be divided into the isolated fatty liver in which there is only accumulation of fat, and nonalcoholic steatohepatitis (NASH), in which there is fat, inflammation, and damage to liver cells.

 

Find out more about Non-Alcoholic Steatohepatitis Treatment Landscape @ Drugs for Non-Alcoholic Steatohepatitis Treatment

 

Non-Alcoholic Steatohepatitis Emerging Drugs Profile

  • Resmetirom: Madrigal Pharmaceuticals
  • MSDC-0602K: Cirius Therapeutics
  • ION224: Ionis Pharmaceuticals
  • HU 6: Rivus Pharmaceuticals
  • HTD 1801: HighTide Biopharma
  • EDP-305: Enanta Pharmaceuticals

 

Non-Alcoholic Steatohepatitis Pipeline Therapeutics Assessment

There are approx. 130+ key companies which are developing the therapies for Nonalcoholic Steatohepatitis. The Non-Alcoholic Steatohepatitis companies which have their Nonalcoholic Steatohepatitis drug candidates in the most advanced stage, i.e. phase III include, Madrigal Pharmaceuticals.

 

DelveInsight’s Non-Alcoholic Steatohepatitis Pipeline Report covers around 150+ products under different phases of clinical development like

  • Late stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates

 

Nonalcoholic Steatohepatitis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Intra-articular
  • Intraocular
  • Intrathecal
  • Intravenous
  • Ophthalmic
  • Oral
  • Parenteral
  • Subcutaneous
  • Topical
  • Transdermal

 

Non-Alcoholic Steatohepatitis Products have been categorized under various Molecule types such as

  • Oligonucleotide
  • Peptide
  • Small molecule 

 

Learn more about the emerging Non-Alcoholic Steatohepatitis Pipeline Therapies @ Non-Alcoholic Steatohepatitis Clinical Trials Assessment

 

Scope of the Non-Alcoholic Steatohepatitis Pipeline Report

  • Coverage- Global
  • Non-Alcoholic Steatohepatitis Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
  • Non-Alcoholic Steatohepatitis Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
  • Non-Alcoholic Steatohepatitis Companies- Madrigal Pharma, Cirius Therapeutics, AstraZeneca, Ionis Pharmaceuticals, NorthSea Therapeutics, Rivus Pharma, Akero Therapeutics, Merck Sharp & Dohme LLC, Enanta Pharmaceuticals, TaiwanJ Pharmaceuticals, Cascade Pharmaceuticals, Hepion Pharmaceuticals, Chipscreen Biosciences, Boston Pharmaceuticals, Bristol-Myers Squibb, GSK plc., Amgen, Altimmune, Inc., Sciwind Biosciences, SCOHIA PHARMA, Galecto Biotech, J2H Biotech, Tiziana Life Sciences, Palobiofarma, Bird Rock Bio, Ascletis, Liminal BioSciences, ARTham Therapeutics, Pliant Therapeutics, Guangdong Zhongsheng Pharmaceutical, Pharmaxis, Melior Pharmaceuticals, TransThera Biosciences, Cerenis Therapeutics, DURECT Corporation, Enzychem Lifesciences, Ildong Pharmaceutical, LG Chem Life sciences, Gmax Biopharm, Albireo Pharma, InorbitTX, Viking Therapeutics, Ildong Pharmaceutical, Thoth Science, and others.
  • Non-Alcoholic Steatohepatitis Therapies- hydroxychloroquine, Berberine, Digoxin tablet, MK-3655, EDP-305 Dose 2, Atorvastatin, L-Carnitine, Ursodeoxycholic Acid, MRI-PDFF, and others.

 

Dive deep into rich insights for new drugs for Non-Alcoholic Steatohepatitis Treatment, Visit @ Non-Alcoholic Steatohepatitis Market Drivers and Barriers, and Future Perspective

 

Table of Content

  1. Introduction
  2. Non-Alcoholic Steatohepatitis Executive Summary
  3. Nonalcoholic Steatohepatitis: Overview
  4. Non-Alcoholic Steatohepatitis Pipeline Therapeutics
  5. Non-Alcoholic Steatohepatitis Therapeutic Assessment
  6. Nonalcoholic Steatohepatitis– DelveInsight’s Analytical Perspective
  7. Late Stage Products (Phase III)
  8. Resmetirom: Madrigal Pharmaceuticals
  9. Drug profiles in the detailed report…..
  10. Mid Stage Products (Phase II)
  11. ION224: Ionis Pharmaceuticals
  12. Drug profiles in the detailed report…..
  13. Early Stage Products (Phase I)
  14. AMG 609: Amgen
  15. Drug profiles in the detailed report…..
  16. Preclinical and Discovery Stage Products
  17. Drug name : Company name
  18. Drug profiles in the detailed report…..
  19. Inactive Products
  20. Nonalcoholic Steatohepatitis Key Companies
  21. Nonalcoholic Steatohepatitis Key Products
  22. Nonalcoholic Steatohepatitis- Unmet Needs
  23. Nonalcoholic Steatohepatitis- Market Drivers and Barriers
  24. Nonalcoholic Steatohepatitis- Future Perspectives and Conclusion
  25. Nonalcoholic Steatohepatitis Analyst Views
  26. Nonalcoholic Steatohepatitis Key Companies
  27. Appendix

 

For further information on the Non-Alcoholic Steatohepatitis Pipeline Therapeutics, reach out @ Non-Alcoholic Steatohepatitis Unmet Needs and Analyst Views

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/behcets-disease-market

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Non-Alcoholic Steatohepatitis Pipeline, FDA Approvals, Clinical Trials Developments and Companies 2023 | AstraZeneca, Ionis Pharmaceuticals, NorthSea Therapeutics, Merck, GlaxoSmithKline and Others

Myelodysplastic Syndrome Pipeline, FDA Approvals, Clinical Trials Development and Companies 2023 | Novartis, Syros Pharmaceuticals, Curis, Ryvu Therapeutics, Chia Tai Tianqing Pharmaceutical Group

DelveInsight’s, “Myelodysplastic Syndrome Pipeline Insight 2023” report provides comprehensive insights about 120+ companies and 150+ pipeline drugs in Myelodysplastic Syndrome pipeline landscape. It covers the Myelodysplastic Syndrome pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Myelodysplastic Syndrome pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Key Takeaways from the Myelodysplastic Syndrome Pipeline Report

  • DelveInsight’s Myelodysplastic Syndrome pipeline report depicts a robust space with 120+ active players working to develop 150+ pipeline therapies for Myelodysplastic Syndrome treatment.
  • The leading companies working in the Myelodysplastic Syndrome Market include Novartis, Syros Pharmaceuticals, Curis, Ryvu Therapeutics, Chia Tai Tianqing Pharmaceutical Group, Amgen, Sanofi, Forma Therapeutics, Agios Pharmaceuticals, AbbVie, Daiichi Sankyo Company, Geron Corporation, Astex Pharmaceuticals, Jazz Pharmaceuticals, Maxinovel Pty., Ltd., Mabwell (Shanghai) Bioscience Co., Ltd., BeiGene, Ellipses Pharma, Treadwell Therapeutics, Bellicum Pharmaceuticals, and others.
  • Promising Myelodysplastic Syndrome Pipeline Therapies in the various stages of development include Venetoclax, Azacitidine, Luspatercept, Epoetin alfa, FG-4592, Lenalidomide 5 mg, and others.
  • December 2023: Celgene announced a study of Phase 3 clinical trials for Luspatercept and Epoetin Alfa. The purpose of this study is to determine the effectiveness of luspatercept (ACE-536) compared to epoetin alfa on red blood cell (RBC) transfusion independence (for at least 12 weeks) with a concurrent hemoglobin increase of at least 1.5 g/dL in participants with anemia due to revised international prognostic scoring system (IPSS-R) very low, low, or intermediate risk myelodysplastic syndromes (MDS) who require RBC transfusions and have never been exposed to erythropoiesis stimulating agent (ESA).
  • December 2023: Bristol-Myers Squibb announced a study of Phase 3 clinical trials for Luspatercept and Epoetin Alfa. The purpose of the study is to compare the efficacy and safety of Luspatercept vs epoetin alfa in the treatment of anemia in adults due to IPSS-R very low, low, intermediate-risk MDS in ESA-naïve participants who are non-transfusion dependent (NTD).
  • December 2023: Celgene announced a study of Phase 1 clinical trials for CC-91633. Study CC-91633-AML-001 is a Phase 1, open-label, dose escalation and expansion, first-in-human (FIH) clinical study of CC-91633 (BMS-986397) in participants with relapsed or refractory acute myeloid leukemia (R/R AML) or in participants with relapsed or refractory higher-risk myelodysplastic syndromes (R/R HR-MDS). The Dose Escalation part (Part A) of the study will enroll participants with R/R AML and R/R HR-MDS and will evaluate the safety and tolerability of escalating doses of CC-91633 (BMS-986397), administered orally, and determine the maximum tolerated dose (MTD) or preliminary recommended Phase 2 dose (RP2D) and schedule.

 

Request a sample and discover the recent advances in Myelodysplastic Syndrome Treatment Drugs @ Myelodysplastic Syndrome Pipeline Outlook Report

 

In the Myelodysplastic Syndrome pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Myelodysplastic Syndrome collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

 

Myelodysplastic Syndrome Overview

Myelodysplastic syndrome (MDS) is a heterogeneous group of hematologic neoplasms classically described as a clonal disorder of hematopoietic stem cells leading to dysplasia and ineffective hematopoiesis in the bone marrow. Some patients with MDS may have a transformation into acute myeloid leukemia (AML). MDS is usually diagnosed in older patients over the age of 65. Clinical manifestations include a decrease in the number of red blood cells (RBC), platelets, and white blood cells (WBC). The disease course is variable.

 

Find out more about Myelodysplastic Syndrome Treatment Landscape @ Drugs for Myelodysplastic Syndrome Treatment

 

Myelodysplastic Syndrome Emerging Drugs Profile

  • MBG453: Novartis
  • Tamibarotene: Syros Pharmaceuticals
  • CA-4948: Curis
  • RVU120: Ryvu Therapeutics

 

Myelodysplastic Syndrome Pipeline Therapeutics Assessment

There are approx. 120+ key companies which are developing the therapies for Myelodysplastic Syndrome. The Myelodysplastic Syndrome companies which have their Myelodysplastic Syndrome drug candidates in the most advanced stage, i.e. Phase III include, Novartis.

 

DelveInsight’s Myelodysplastic Syndrome Pipeline Report covers around 150+ products under different phases of clinical development like

  • Late stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates

 

Myelodysplastic Syndrome pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Oral
  • Intravenous
  • Subcutaneous
  • Parenteral
  • Topical

 

Myelodysplastic Syndrome Products have been categorized under various Molecule types such as

  • Recombinant fusion proteins
  • Small molecule
  • Monoclonal antibody
  • Peptide
  • Polymer
  • Gene therapy

 

Learn more about the emerging Myelodysplastic Syndrome Pipeline Therapies @ Myelodysplastic Syndrome Clinical Trials Assessment

 

Scope of the Myelodysplastic Syndrome Pipeline Report

  • Coverage- Global
  • Myelodysplastic Syndrome Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
  • Myelodysplastic Syndrome Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
  • Myelodysplastic Syndrome Companies- Novartis, Syros Pharmaceuticals, Curis, Ryvu Therapeutics, Chia Tai Tianqing Pharmaceutical Group, Amgen, Sanofi, Forma Therapeutics, Agios Pharmaceuticals, AbbVie, Daiichi Sankyo Company, Geron Corporation, Astex Pharmaceuticals, Jazz Pharmaceuticals, Maxinovel Pty., Ltd., Mabwell (Shanghai) Bioscience Co., Ltd., BeiGene, Ellipses Pharma, Treadwell Therapeutics, Bellicum Pharmaceuticals, and others.
  • Myelodysplastic Syndrome Pipeline Therapies- Venetoclax, Azacitidine, Luspatercept, Epoetin alfa, FG-4592, Lenalidomide 5 mg, and others.

 

Dive deep into rich insights for new drugs for Myelodysplastic Syndrome treatment, Visit @ Myelodysplastic Syndrome Market Drivers and Barriers, and Future Perspective

 

Table of Content

  1. Introduction
  2. Executive Summary
  3. Myelodysplastic Syndrome: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Myelodysplastic Syndrome– DelveInsight’s Analytical Perspective
  7. Late Stage Products (Phase III)
  8. MBG453: Novartis
  9. Drug profiles in the detailed report…..
  10. Mid Stage Products (Phase II)
  11. CA-4948: Curis
  12. Drug profiles in the detailed report…..
  13. Early Stage Products (Phase I)
  14. RVU120: Ryvu Therapeutics
  15. Drug profiles in the detailed report…..
  16. Preclinical and Discovery Stage Products
  17. Drug name: Company name
  18. Drug profiles in the detailed report…..
  19. Inactive Products
  20. Myelodysplastic Syndrome Key Companies
  21. Myelodysplastic Syndrome Key Products
  22. Myelodysplastic Syndrome- Unmet Needs
  23. Myelodysplastic Syndrome- Market Drivers and Barriers
  24. Myelodysplastic Syndrome- Future Perspectives and Conclusion
  25. Myelodysplastic Syndrome Analyst Views
  26. Myelodysplastic Syndrome Key Companies
  27. Appendix

 

For further information on the Myelodysplastic Syndrome Pipeline Therapeutics, reach out @ Myelodysplastic Syndrome Unmet Needs and Analyst Views

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/behcets-disease-market

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Myelodysplastic Syndrome Pipeline, FDA Approvals, Clinical Trials Development and Companies 2023 | Novartis, Syros Pharmaceuticals, Curis, Ryvu Therapeutics, Chia Tai Tianqing Pharmaceutical Group

StealthWing4k Drone Launches The Highest Customer Rated Drone on The Internet

Unique Christmas Gift Ideas of 2023

Drone cameras are the future of the world of photography, this technology is admired for its versatility since it records for different angles and gives off amazing results in the forms of pictures and videos. 

There are many brands and companies that have come up with their drone camera designs and all of them have distinct aspects to them. People buy Drone cameras according to their needs and the prices the companies are offering, this helps the amateurs choose what is best for them and the same goes for professionals who are looking for Drone cameras.

The StealthWing4k Drone 4K cameras are another addition to the world of photography and further details about this latest invasion are mentioned as follows.

The StealthWing4k Drone Camera is a hybrid technology drone device for people who are fond of photography. This product is for everyone wanting to get their hands on something that is not only new in terms of technology but also has additional features and can last long. The StealthWing4k Drone is the perfect option for those looking for a one-time investment in a flying camera with all the specifications jotted down below.

The StealthWing4k Drone camera is a lightweight, drone camera which facilitates the user by its dynamic foldable body. Its long flight time and higher flight height grab the most attention while the convenient body structure and other features of this drone make it worth investing in.

The Fanatically Alterable Body:

One of the main concerns of drone photographers is how to travel with a device as fragile as the drone camera? but the StealthWing4k Drone has put an end to this problem by inventing a foldable body design that alters its structure to let the user carry it along pretty easily, meaning now you can have the drone camera folded inside in your bag pack and carry it wherever you want to.

Easy-to-carry Transportable Device:

The StealthWing4k Drone not only facilitates the user with its alterable body but also is easy-to-carry since it is comparatively light in weight which happens to be a big plus. This product is carriageable for two reasons and its light has to be one of them. Other than this, the lighter weight of this design also lets makes it more controllable for beginners while its aerodynamic body contributes to it.

High Definition Camera Result:

A drone camera can be all fancy, small, and expensive with the latest features but if it does not deliver a good quality of photos and videos then the sole reason for purchasing it becomes useless. In the case of StealthWing4k Drone, the video and picture quality is promised to be High Definition. This enables the handler to be more active and the beginners to be interested in the art of photography because good picture quality decreases the extra effort one needs to put in to get exceptional results.

Slow Motion Mode:

One of the features of the StealthWing4k Drone camera is the Slow motion video recording feature. This part of the camera works so efficiently delivering the best quality videos in such an aesthetic way that one can not help falling for it. The High definition video recording quality makes the slo-mo videos even more bewitching for the photographer as well as the viewer.

Faster In Speed:

The speed at which drone cameras fly matters a lot when it comes to the results because drone cameras are primarily bought for aerial views. The StealthWing4k Drone has a comparatively faster speed and this makes it outstanding in the competitive market full of drone cameras. It can cover up to 30 miles in the time span of 60 minutes which is pretty impressive whereas its time of flight is also commendable being a good 30 minutes in the air.

Battery Life:

The drone cameras usually come with average battery health and traditional drone cameras are too battery consuming ultimately resulting in low active time however the StealthWing4k Drone has a high-functioning body which is the least to find in other drones. The 1 x 3.7v 500 mah LIPO battery of this product allows it to function for at least 30 minutes while only taking about an hour or 70 minutes. The StealthWing4k Drone is controlled via a remote-control widget that runs on a 3 x 1.5AA battery which is also good to last for a longer period of time.

The StealthWing4k Drone is an all-in-one package that offers multiple features in a uniquely designed body. This camera has an 80-100 M R/C distance together with an FPV range of approximately 30 meters. This drone is available at its official site at a pretty discounted cost and the website is also offering different discounted packages for different types of buyers, for instance, the beginners can have one sort of package while the professionals and the people who are wanting to purchase the device in bulk can also have a look at the discount packages. The StealthWing4k Drone is a foldable drone camera that delivers High-Definition photos and videos. Along with the slow-mo video recording feature, this camera confines many other features that astound the users in every use. The StealthWing4k Drone is recommended to invest in since it promises longevity and costs quite economical too so the buyers can have an affordable purchase but a quality product.

Media Contact
Company Name: StealthWing4k Drone
Contact Person: Margot Robbie
Email: Send Email
Country: United States
Website: https://rebrand.ly/StealthWing

 

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: StealthWing4k Drone Launches The Highest Customer Rated Drone on The Internet